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C
omplex I is the largest of the mitochondrial respiratory
chain enzyme complexes, consisting of at least 46
subunits, seven of which are encoded by mtDNA.
Deficiency of complex I is the most common respiratory chain
defect, and can be caused by mutations in both nuclear and
mtDNA encoded genes. It has a wide range of clinical
presentations, from lethal infantile mitochondrial disease to
isolated myopathy.1–3 Mitochondrial encephalopathy, lactic
acidosis and stroke-like episodes (MELAS) is one of the
syndromes associated with complex I deficiency and in
approximately 80% of cases is caused by a mutation,
3243ARG, in the mitochondrial tRNALeu(UUR) gene
(MTTL1). Other mutations in MTTL1 and other transfer
RNA genes (MTTF, MTTV, MTTQ) account for most of the
remainder of cases.4 However, a number of mutations in the
mitochondrial MTND subunit genes of complex I have also
been reported to cause MELAS, most notably in MTND55 and
to a lesser extent in MTND6.6
In stark contrast, there are presently no mutations in the
MTND1 subunit gene associated with MELAS. There are
several mutations in MTND1 associated with Leber’s heredi-
tary optic neuropathy (LHON) which may be pathogenic, but
only one, the 3460GRA mutation, that has robust evidence,
including cell biology studies, for pathogenicity.7–9 Here we
report three unrelated patients with MELAS and isolated
complex I deficiency in skeletal muscle and cultured
fibroblasts due to previously unreported mutations in the
MTND1 gene. Evidence confirming the pathogenic nature of
these mutations includes data from cell fusion experiments
and blue native polyacrylamide gel electrophoresis (BN-
PAGE), the latter confirming a crucial role for the ND1
subunit in the assembly of complex I holoenzyme.10
PATIENTS
Patient 1
Patient 1, a white male, presented at 4 years of age with a
3 month history of increasing tiredness, clumsiness, frequent
falls, and weakness of his left side. On examination he had
increased tone and brisk reflexes in his left leg and walked
with a hemiplegic gait. Magnetic resonance imaging (MRI)
revealed lesions of the right lentiform and caudate nuclei. He
made a partial recovery, but at 7 years of age presented with
right sided facial twitching and speech difficulties. EEG
suggested focal seizures, and MRI revealed new lesions of the
right thalamus, left basal ganglia, and bifrontal cortical
regions. Magnetic resonance spectroscopy revealed increased
levels of lactate in these areas. CSF and blood lactate levels
were 2.7 mmol/l and 1.3 mmol/l respectively (normal
,2.5 mmol/l for both). Skeletal muscle histology and enzyme
histochemistry were normal, but electron microscopy indi-
cated focal subsarcolemmal accumulation of mitochondria.
The seizures resolved over 6 months. At 9 years of age he had
a period of lethargy, slurred speech, and relatively poor
functioning lasting 2 months. MRI revealed extension of the
lesions in the left basal ganglia and right frontal cortex. He
has had no further acute episodes and at 10 years old he
walks independently but requires a wheelchair for long
distances. He has retained normal intelligence and there is no
family history of note. On examination he has no cranial
Abbreviations: BN-PAGE, blue native polyacrylamide gel
electrophoresis; CS, citrate synthase; CT, computed tomography; LHON,
Leber’s hereditary optic neuropathy; MELAS, mitochondrial
encephalopathy, lactic acidosis, and stroke-like episodes; MRI, magnetic
resonance imaging; mtDNA, mitochondrial DNA; mt-tRNA,
mitochondrial transfer RNA; RFLP, restriction fragment length
polymorphism
Key points
N Mitochondrial encephalopathy, lactic acidosis, and
stroke-like episodes (MELAS) is one of many clinical
presentations associated with mutations in mitochon-
drial DNA (mtDNA) and a biochemical deficiency
of respiratory chain complex I. While the ‘common’
3243ARG mutation in the mitochondrial tRNALeu(UUR)
(MTTL1) gene is detected in approximately 80% of
patients with MELAS, the aetiology of the remaining
20% is heterogeneous, with different causative muta-
tions occurring in MTTL1, other mitochondrial tRNA
(mt-tRNA) genes, and the MTND genes encoding
subunits of complex I.
N We report three unrelated patients with MELAS in
whom the 3243ARG mutation could not be detected,
but who expressed a specific deficiency of complex I
activity in both skeletal muscle and cultured fibroblasts.
Targeted sequencing of mt-tRNA and MTND genes
revealed that each patient harboured a different novel
mutation in the MTND1 subunit gene of complex I
(3697GRA, 3946GRA, and 3949TRC), each of
which predicted an amino acid change. The failure to
restore complex I activity upon fusion of patient cells
with a cell line lacking mtDNA (r0 cells) confirmed
pathogenicity for each of these mutations, all of which
appear to perturb the assembly or turnover of complex I.
N Our finding of three novel mutations in the MTND1
gene causing MELAS is supportive of recent papers
highlighting the importance of mtDNA mutations in the
aetiology of childhood respiratory chain complex I
deficiency and underlines the importance of a cohesive
diagnostic strategy where molecular genetic investiga-
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nerve signs and normal proximal power, but increased tone
and brisk reflexes, especially in the lower limbs.
Patient 2
Patient 2, a white female, had normal developmental
milestones until 5 years of age, when anxiety issues and
schooling difficulties became evident. From 11 years of age
she developed hearing problems, and high tone deafness was
confirmed at when she was 14 years old. She presented at
14 years of age with frontal headaches, vomiting, and
multiple left sided focal seizures, which became generalised
over a 24 hour period. MRI and computed tomography (CT)
of the head showed a right parietal lobe ‘watershed’ infarct,
which showed some progression 7 days after the onset of
seizures. Subsequent MRI and CT scans revealed further
ischaemic areas in both occipital regions, and in the parietal,
temporal, and frontal lobes. CSF and plasma lactate levels
were elevated at 10.3 mmol/l and at 3.5 mmol/l respectively.
Skeletal muscle biopsy was normal on both light and electron
microscopy. Recurrent strokes complicated by seizures,
episodes of cortical blindness of variable completeness, and
other neurological deficits have occurred, leaving her with a
moderate intellectual disability. A maternal half sister and
full sister are reported to tire easily, as does her mother, who
also suffers from high tone deafness and mild glucose
intolerance.
Patient 3
This male patient of Chinese origin presented at 14 years of
age with a short history of left sided upper limb focal
seizures. The EEG showed focal spike and slow wave
discharges over the right parasagittal region. A few months
later, he presented with headache and blurred vision. On
examination he had a left homonymous hemianopia with
macular sparing, and MRI showed lesions in the right
occipital and posterior frontal cortex. His visual problems
resolved, but over the following year he had episodes of
altered sensation in his limbs. A further MRI showed new T2
hyperintensity lesions in the anterior aspect of the left
occipital lobe, the medial right parietal cortex, and the
anterior frontal cortex. The basal ganglia were not affected.
His CSF and plasma lactate levels were 3.4 mmol/l and
3.0 mmol/l respectively. Skeletal muscle enzyme histochem-
istry showed subsarcolemmal accumulations of mitochondria
and EM revealed a moderately increased number of large,
abnormally shaped mitochondria with abnormal cristae and
excess lipid. At 16 years of age he has normal intelligence and
little of note on examination. He has regular episodes of focal
left hand seizures that are difficult to control but have not
generalised. Medications include carbamazepine, coenzyme
Q10, riboflavin, and vitamin C. His mother and an older sister




The activities of the individual respiratory chain complexes
and the mitochondrial matrix marker enzyme citrate
synthase were measured in skeletal muscle homogenates
and mitochondrial fractions isolated from cultured cells as
described previously.2 11
mtDNA analysis
Total DNA was extracted from tissues, cultured cells, urine
sediment, and blood by standard procedures. Manual
sequencing of the MTTL1 gene was performed using a
ThermoSequenase radiolabeled terminator cycle sequencing
kit (USB Corporation, Cleveland, OH, USA). For automated
sequencing, the coding region of the mitochondrial genome
was amplified using a series of overlapping oligonucleotide
primer pairs and sequenced with a BigDye terminator cycle
sequencing kit as described previously.12 Sequence data were
analysed using Navigator and Factura software (Applied
Biosystems, Warrington, UK) and compared to the revised
Cambridge reference sequence of human mtDNA.13
Quantification of mtDNA heteroplasmy
Putative pathogenic sequence variants in tissues and cells
from the patients and other family members were further
investigated by last hot cycle PCR-restriction fragment length
polymorphism (RFLP) analysis. Details of the oligonucleotide
primers and restriction endonucleases used for each of the
patients are provided in table 1, along with the expected
fragment sizes after digestion. The relative proportions of
normal and mutated mtDNA genomes in different tissues
were determined by the addition of 5mCi [a-32P]-dCTP
(3000 Ci/mmol) prior to the last cycle of the PCR. Labelled
products were digested with 10 U of the appropriate
restriction endonuclease (table 1), separated through a 12%
non-denaturing polyacrylamide gel, and the radioactivity in
each fragment quantified using ImageQuant software
(Molecular Dynamics, Sunnyvale, CA, USA).
Cell biology studies
Cells were cultured in Dulbecco’s modified Eagle’s medium
(JRH Biosciences, Lenexa, KS, USA), supplemented with 10%
fetal calf serum (JRH Biosciences) and 50 mmol/l uridine.
Generation of antibiotic resistant cell l ines
G418 resistance and increased growth potential were
conferred on a control fibroblast cell line and the
143BTK-r0 osteosarcoma cell line as described.14 Similarly,
patient fibroblasts were transfected with Hygromycin B
resistance and SV40 T antigen via pGKHygT, derived from
the pGKHyg plasmid (gift of Dr R Saffery). Antibiotic
resistant clones were isolated after selection with
Hygromycin B (Roche Diagnostics Australia, Castle Hill,
NSW, Australia).
Generation of hybrids
Two cell lines with different antibiotic resistance were
co-cultured until confluent and fused using polyethylene
glycol (PEG 1500, 50% solution in 15 mmol/l HEPES;
Roche Diagnostics Australia, Castle Hill, NSW, Australia).
Heterokaryons were selected in medium containing both
G418 (200 mg/ml) and hygromycin B (100 mg/ml). Dual
antibiotic resistant hybrids were passaged in the selective
medium at least twice after the parental and ‘‘self self’’ fused
cells had died (usually after 5–10 days) before analysis of
complex I activity. Cell fusion experiments and complex I
enzyme analysis were performed in duplicate.
Protein analysis
The amount and size of assembled complex I was studied by
BN-PAGE and immunoblotting using mitochondria isolated




Respiratory chain enzymes in skeletal muscle homogenates
and cultured skin fibroblasts from each patient were
consistent with an isolated defect of complex I according to
the criteria described previously2 (table 2). For patient 1,
complex I activity in muscle was not clearly deficient when
expressed relative to protein or as a ratio to the mitochondrial
matrix enzyme citrate synthase (CS), but was deficient when
expressed relative to complex II (23% of control mean). All
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respiratory chain enzymes measured except complex I were
180–280% of control means relative to CS in that sample,
reflecting mitochondrial proliferation.
Identification of pathogenic mutations
Sequence analysis of the MTTL1 gene was normal for all three
patients. This prompted sequencing of the ND and mt-tRNA
coding regions of the mitochondrial genome. In addition to
recognised polymorphisms, each patient had a number of
changes that had not been reported previously in public data-
bases16 17 (see also http://www.genpat.uu.se/mtDB/polysites.
html). While many changes were synonymous or occurred
in non-conserved regions of the genome, each patient had
a different heteroplasmic mutation, predicted to change a
conserved amino acid of the MTND1 gene. These mutations,
(3697GRA (G131S), 3946GRA (E214K) and 3949TRC
(Y215H)), were therefore potentially pathogenic and
entirely consistent with a resultant complex I deficiency.
PCR-RFLP assays were developed for each of these
sequence variants, and mutant loads were determined by
last cycle hot PCR (table 1). Patient 1 had 80% and 79% of the
3697GRA mutation in skeletal muscle and fibroblasts
respectively. The mutant load was 3% in blood from his
mother, but no mutation was detected in blood from his two
sisters (fig 1A), two maternal aunts, maternal uncle, or
maternal grandmother (not shown), all of whom were
asymptomatic.
Patient 2 harboured somewhat lower mutant load, with
60% of the 3946GRA mutation in muscle, 45% in fibroblasts,
and 37% in blood. No mutation was detected in blood or
urine sediment from her mother, while 3% mutant load was
detected in urine sediment from her sister (fig 1B), implying
that although the mother harbours the mutation in ovarian
tissue, it may be selected against in mitotic tissues as
previously reported for the 3243ARG MTTL1 mutation.18
Patient 3 had 93% of the 3949TRC mutation in muscle,
88% in fibroblasts, and 45% in blood. Thus it appears likely
that the 3949TRC mutation is also selected against in blood.
No mutation was detected in blood from his asymptomatic
mother and two brothers (fig 1C).
We also used PCR-RFLP analysis to screen for the
3697GRA, 3946GRA, and 3949TRC mutations in 68
complex I deficient paediatric patients in whom no causative
mutation had been found. None of these mutations was
detected in these patients.
Cell biology studies
When fibroblasts from a complex I deficient patient with a
presumed nuclear DNA defect were fused with the
143BTK-r0 osteosarcoma cell line, the hybrids showed
restoration of complex I activity. However, fusion of
fibroblasts from the three patients reported here and the
143BTK-r0 osteosarcoma cell line failed to restore complex I
activity (fig 2). As the r0 cell line contains no mtDNA, lack of
phenotypic rescue in the hybrids indicates that the nucleus of
the r0 cell line is unable to correct the complex I defect. These
results imply that the complex I defect in the three patient
cell lines is of mtDNA origin19 20 and confirm that the novel
mutations described here are causative.
Protein studies
Analysis of the intact complex after separation by BN-PAGE
with an antibody to the 39 kDa subunit of complex I revealed
dramatically reduced levels of fully assembled complex I for
each of the three patients (25% for 3697GRA, 11% for
3946GRA, and 12% for 3949TRC) compared to a control
fibroblast cell line (fig 3).
DISCUSSION
All three patients presented with a classical MELAS
phenotype and suggestive family history, but without
evidence of 3243ARG or other mutations in the MTTL1
gene. The finding of an isolated complex I deficiency, with
normal complex IV/CS and complex IV/complex II ratios in
skeletal muscle, led us to investigate a possible mtDNA
mutation as the cause of the clinical disease. The elevation of
Table 1 PCR-RFLP analysis of putative pathogenic MTND1 gene mutations in the three patients
Sequence
variant Primers Primer sequences (59 to 39)
Restriction
enzyme Expected fragment sizes (bp)
Patient 1
(3697GRA)
L3607–3627 GGCCTCCTATTTATTCTAGCC BclI Wildtype: 189 R137 +52
H3795–37776 GGAGAGGTTAAAGGAGCCAC 3697GRA: 189 R103 +52 +34
Patient 2
(3946GRA)
L3875–3894 TAGCAGAGACCAACCGAACC TaqI Wildtype: 157 R87 +43 +27
H4031–4011 AAGATTGTAGTGGTGAGGGTG 3946GRA: 157 R130 +27
Patient 3
(3949TRC)
L3928–3948 tgtaaaacgacggccagtGTCTCAGGCTTCAACATCGTA RsaI Wildtype: 222 R188 +34
H4113–4094 caggaaacagctatgaccCAGGGAGGTTAGAAGTACGG 3949TRC: 222 R150 +38 +34
Details of the oligonucleotide primers, restriction endonucleases, and expected fragment sizes following enzyme digestion are given.
For patient 3, primers have additional M13 sequence (shown in lower case), while mismatch nucleotides are in bold.
Table 2 Residual complex I activities in skeletal muscle homogenates and isolated
fibroblast mitochondria
Complex
% Activity (observed range for controls)
Patient 1 Patient 2 Patient 3
Muscle Fibroblasts Muscle Fibroblasts Muscle Fibroblasts
CoI 68 (43–204) 18 (46–191) 2 (43–204) 27 (46–191) 27 (43–204) 28 (46–191)
CoI/CS 60 (36–167) 35 (50–145) 2 (36–167) 34 (50–145) 19 (36–167) 24 (50–145)
CoI/CoII 23 (51–153) 19 (46–169) 2 (51–153) 14 (46–169) 11 (51–153) 13 (46–169)
All assays were performed in duplicate.
Complex I (CoI) activity was expressed as percentage of the mean of controls (for skeletal muscle homogenates,
n=16, mean activity 44 nmol/min/mg, observed range 19–90; for fibroblast mitochondria, n=35, mean activity
74 nmol/min/mg, observed range 34–141) and relative to the activity of citrate synthase (CoI/CS) and complex II
(CoI/CoII).2
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complex II observed in muscle from patients 1 and 3 is
entirely consistent with the mitochondrial proliferation noted
in their muscle biopsies, a frequent histological finding in
many mtDNA disorders.
Sequencing revealed a different novel mutation in the
MTND1 subunit gene of each patient. These mutations were
heteroplasmic in skeletal muscle and cultured skin fibro-
blasts, where the mutant load also correlated with the
complex I defect. Patient 2 had a somewhat lower mutant
load (60% in muscle and 45% in fibroblasts), but this is not
without precedent in complex I genes, as comparably low
mutant loads of the 13513GRA (MTND5) have been
associated with Leigh disease.14 The mutations were not
present in three large mtDNA sequence databases (see
Results) nor were they present in 68 complex I deficient
children in whom no causative mutations had been
identified. Pathogenicity was confirmed by the failure to
restore complex I activity upon fusion of fibroblasts with a
cell line (r0) containing no mtDNA (fig 2). In these
circumstances, patient mitochondria are observed in a
different nuclear background and rescue of the biochemical
defect is therefore evidence of a nuclear origin for the
complex I deficiency.19 20
Figure 1 Quantification of the level of mutated mtDNA in patients and
other relatives by PCR-RFLP analysis. Details of the oligonucleotide
primers, restriction endonucleases and expected digestion products are
given in table 1. (A) Patient 1 (3697GRA); (B) patient 2 (3946GRA);
(C) patient 3, (3949TRC). U, uncut sample; C, control; M, skeletal
muscle; F, fibroblasts; B, blood. Lanes 1–3 show blood from the mother
and two sisters of patient 1; lanes 4–6 show blood and urinary sediment
from the mother and urinary sediment from the sister of patient 2; lanes
7–10 show blood taken from the mother, father, and two brothers of
patient 3.
→ → →
Figure 2 Complex I activity (expressed relative to citrate synthase; CS)
in patient cell lines and hybrids. The light grey columns show complex I
activity in transformed fibroblasts. Open bars show complex I activity in
hybrids between control transformed fibroblasts and transformed
fibroblasts from either a control, patient 1, 2, 3, or a patient from a
consanguineous pedigree with a presumed nuclear DNA mutation. Dark
grey columns show complex I activity in hybrids between the 143BTK-r0
osteosarcoma cell line and the control or patient cell lines. The error bars
represent the observed range for all complex I measurements for that cell
line, which were as follows: control transformed fibroblast cell line
(n=23); parental transformed fibroblasts from patients 1, 2, and 3
(n=1); ‘‘nuclear’’ patient transformed fibroblasts (n=8); patient 16r0
hybrid (n=4); and all other fusions (both with control and r0 cell lines)
(n=2).
Figure 3 Analysis of levels of assembled complex I by BN-PAGE.
Mitochondria isolated from patient fibroblasts and a control (Con) were
solubilised in dodecyl maltoside and subjected to BN-PAGE and
subsequent Western blot analysis using antibodies specific for the
complex I 39 kDa subunit and complex II 70 kDa subunit. The amount of
fully assembled complex I relative to complex II was estimated by
densitometry of the BN-PAGE immunoblot and shown to be 25% for
patient 1, 11% for patient 2, and 12% for patient 3.
Mitochondrial ND1 mutations in MELAS 787
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At present, there is only one mutation in the MTND1 gene
with compelling evidence for pathogenicity, 3460GRA,
which is thought to cause LHON.7–9 We believe the novel
mutations described here represent three further pathogenic
mutations in MTND1. Firstly, they all change conserved
amino acids of complex I and are associated with complex I
deficiency in patient tissues and in r0 hybrids. Secondly, they
are heteroplasmic, with much higher levels of the mutation
present in patient tissues than in unaffected relatives. Finally,
they are absent both in large numbers of controls and in
asymptomatic maternal relatives of the probands.
ND1 is one of the most conserved complex I subunits.21
Situated in the hydrophobic arm of the L shaped complex I
protein, it forms eight transmembrane spanning domains
that are postulated to be involved in ubiquinone binding and
proton pumping,22 processes known to be disrupted by
mutations in homologous bacterial genes. Specific impair-
ment of ubiquinone reductase activity has been demon-
strated following mutation of the nqo8 gene (homologous
with human ND1) of Paracoccus denitrificans.23 Furthermore,
studies of the NQO8 subunit suggest that glutamate residues
located close to helices E and F on the matrix side of the
mitochondria are involved in quinone binding and reduc-
tion.24 In Rhodobacter capsulatus, the ND1 homologue NUOH
and the NUOD subunit, which is the homologue of the
nuclear encoded 49 kD subunit of complex I in mitochondria,
also appear to be involved in ubiquinone binding.25
Interestingly, the three novel mutations reported here, in
common with mutations described in bacterial homologues
of MTND1 and the LHON mutation 3460GRA, also cause an
amino acid change in the hydrophilic loops that face the
mitochondrial matrix (fig 4). The 3697GRA (G131S)
mutation in patient 1 occurs at a highly conserved residue
in the loop between transmembrane domains C and D.21 26
The 3946GRA (E214K) and 3949TRC (Y215H) mutations in
patients 2 and 3 are in the glutamic acid rich hydrophilic loop
between transmembrane domains E and F, one of the most
conserved regions of the ND1 subunit.21 26 The mutations in
patients 2 and 3 change the charge of the amino acid and are
both predicted to abolish a b turn in the ND1 protein.27
At the protein level, the mutations in our MELAS patients
appear to affect complex I assembly or turnover (fig 3). The
BN-PAGE results demonstrate low levels of fully assembled
complex I in fibroblasts from the three patients, with the
3946GRA (E214K) and 3949TRC (Y215H) mutations in
patients 2 and 3 appearing to be more detrimental. The ND1
subunit is thought to be incorporated into the complex I
structure at an early stage of its assembly.10 This implies that
the decreased levels of fully assembled complex I are due to
impaired assembly of complex I, with consequent degrada-
tion of unincorporated subunits. A similar mechanism has
been demonstrated for the cytochrome c oxidase subunits in
patients with mutations in SURF1.28
It is interesting to note that all three patients with MTND1
mutations expressed a complex I defect in cultured fibro-
blasts. Similarly, we found that all of eight patients with
mutations in the MTND3,15 MTND5,14 and MTND629 subunit
genes who presented with Leigh disease or other infantile
encephalopathies also expressed complex I deficiency in
fibroblasts. By contrast, our experience with five patients
with complex I deficiency caused by mutations in MTTL1
(two with 3243ARG and one each with 3250TRC, 3303CRT,
and 3242G.A)2 is that all but the 3242G.A patient had low
mutant loads and normal complex I activity in fibroblasts
(results not shown). Thus patients with mutations in MTND
subunit genes express a complex I defect in fibroblasts more
often than those with MTTL1 mutations.
Liolitsa et al have proposed that the MTND5 gene is a hot
spot for mutations causing MELAS, and note four mutations
in this gene that have been associated with the syndrome:
13513GRA, 13514ARG, 12770GRA, and 13045ARC.5
Certainly, it would appear that the aetiology of MELAS is
diverse and that following exclusion of the 3243ARG
mutation, a targeted sequencing approach should be directed
by the results of muscle biochemistry. In patients with
MELAS, isolated complex I deficiency has proved an
important indicator of a MTND gene mutation and our
finding of three novel mutations in three unrelated patients
suggests that the MTND1 gene may also be a hot spot for
mutations that cause this devastating disease.
→ → →
→ Figure 4 Predicted structure of human
ND1 showing the eight transmembrane
spanning domains (http://sosui.
proteome.bio.tuat.ac.jp). The three
novel mutations in patients 1, 2, and
3 (shown in bold), together with the
pathogenic 3460GRA LHON mutation
are indicated, highlighting their
positions within conserved, hydrophilic,
extramembrane loops. The
corresponding amino acid sequences
from several species surrounding the
mutations (from residues 125–140 and
192–229 of the human sequence) are
shown. The three residues affected by
the novel mutations (in bold) are highly
conserved.
788 Kirby, McFarland, Ohtake, et al
www.jmedgenet.com
 group.bmj.com on January 18, 2010 - Published by jmg.bmj.comDownloaded from 
ACKNOWLEDGEMENTS
This work was supported by grants from the National Health and
Medical Research Council of Australia, the Australian Research
Council, the Muscular Dystrophy Association of the USA, the
Wellcome Trust, the Muscular Dystrophy Campaign UK and the
Newcastle upon Tyne Hospitals NHS Trust. R McFarland is an MRC
Clinician Scientist and D R Thorburn is an NHMRC Senior Research
Fellow.
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
D M Kirby, D R Thorburn, Murdoch Childrens Research Institute, Royal
Children’s Hospital, Melbourne, Australia
D M Kirby, D R Thorburn, Genetic Health Services Victoria, Royal
Children’s Hospital, Melbourne, Australia
D M Kirby, D R Thorburn, Department of Paediatrics, University of
Melbourne, Australia
R McFarland, D M Turnbull, R W Taylor, Mitochondrial Research
Group, School of Neurology, Neurobiology and Psychiatry, University
of Newcastle upon Tyne, UK
A Ohtake, C Dunning, M T Ryan, Department of Biochemistry, La Trobe
University, Melbourne, Australia
A Ohtake, Department of Paediatrics, Saitama Medical School,
Moroyama, Saitama, Japan
C Wilson, Metabolic Service, National Testing Centre, Starship
Children’s Hospital, Auckland, New Zealand
D Ketteridge, Department of Chemical Pathology, Women’s and
Children’s Hospital, Adelaide, Australia
Conflicts of interest: none declared
Correspondence to: Dr R W Taylor, Mitochondrial Research Group,
School of Neurology, Neurobiology and Psychiatry, University of
Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK; r.w.taylor@
ncl.ac.uk
Received 12 March 2004
Revised 6 April 2004
Accepted 8 April 2004
REFERENCES
1 Robinson BH, De Meirleir L, Glerum M, Sherwood G, Becker L. Clinical
presentation of mitochondrial respiratory chain defects in NADH-coenzyme Q
reductase and cytochrome oxidase: clues to pathogenesis of Leigh disease.
J Pediatr 1987;110:216–22.
2 Kirby DM, Crawford M, Cleary MA, Dahl HH, Dennett X, Thorburn DR.
Respiratory chain complex I deficiency: an underdiagnosed energy generation
disorder. Neurology 1999;52:1255–64.
3 Loeffen JL, Smeitink JA, Trijbels JM, Janssen AJ, Triepels RH, Sengers RC, van
den Heuvel LP. Isolated complex I deficiency in children: clinical, biochemical
and genetic aspects. Hum Mutat 2000;15:123–34.
4 DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases.N Engl J Med
2003;348:2656–68.
5 Liolitsa D, Rahman S, Benton S, Carr LJ, Hanna MG. Is the mitochondrial
complex I ND5 gene a hot-spot for MELAS causing mutations? Ann Neurol
2003;53:128–32.
6 Ravn K, Wibrand F, Hansen FJ, Horn N, Rosenberg T, Schwartz M. An
mtDNA mutation, 14453GRA, in the NADH dehydrogenase subunit 6
associated with severe MELAS syndrome. Eur J Hum Genet 2001;9:805–9.
7 Huoponen K, Vilkki J, Aula P, Nikoskelainen EK, Savontaus ML. A new
mtDNA mutation associated with Leber hereditary optic neuroretinopathy.
Am J Hum Genet 1991;48:1147–53.
8 Majander A, Huoponen K, Savontaus ML, Nikoskelainen E, Wikstrom M.
Electron transfer properties of NADH2ubiquinone reductase in the ND1/
3460 and the ND4/11778 mutations of the Leber hereditary optic
neuroretinopathy (LHON). FEBS Lett 1991;292:289–92.
9 Howell N, Bindoff LA, McCullough DA, Kubacka I, Poulton J, Mackey D,
Taylor L, Turnbull DM. Leber hereditary optic neuropathy: identification of the
same mitochondrial ND1 mutation in six pedigrees. Am J Hum Genet
1991;49:939–50.
10 Antonicka H, Ogilvie I, Taivassalo T, Anitori RP, Haller RG, Vissing J,
Kennaway NG, Shoubridge EA. Identification and characterization of a
common set of complex I assembly intermediates in mitochondria from
patients with complex I deficiency. J Biol Chem 2003;278:43081–8.
11 Rahman S, Blok RB, Dahl HHM, Danks DM, Kirby DM, Chow CW,
Christodoulou J, Thorburn DR. Leigh syndrome: clinical features and
biochemical and DNA abnormalities. Ann Neurol 1996;39:343–51.
12 Taylor RW, Taylor GA, Durham SE, Turnbull DM. The determination of
complete human mitochondrial DNA sequences in single cells: implications for
the study of somatic mitochondrial DNA point mutations. Nucleic Acids Res
2001;29:E74–4.
13 Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM,
Howell N. Reanalysis and revision of the Cambridge reference sequence for
human mitochondrial DNA. Nat Genet 1999;23:147.
14 Kirby DM, Boneh A, Chow CW, Ohtake A, Ryan MT, Thyagarajan D,
Thorburn DR. Low mutant load of mitochondrial DNA G13513A mutation can
cause Leigh’s disease. Ann Neurol 2003;54:473–8.
15 McFarland R, Kirby DM, Fowler KJ, Ohtake A, Ryan MT, Amor DJ,
Fletcher JM, Dixon JW, Collins FA, Turnbull DM, Taylor RW, Thorburn DR. De
novo mutations in the mitochondrial ND3 gene as a cause of infantile
mitochondrial encephalopathy and complex I deficiency. Ann Neurol
2004;55:58–64.
16 MITOMAP: A Human Mitochondrial Genome Database. http://
www.mitomap.org, 2004.
17 MitoKor. http://www.mitokor.com/science/560mtdnas.php.
18 Rahman S, Poulton J, Marchington D, Suomalainen A. Decrease of 3243
ARG mtDNA mutation from blood in MELAS syndrome: a longitudinal study.
Am J Hum Genet 2001;68:238–40.
19 Munaro M, Tiranti V, Sandona D, Lamantea E, Uziel G, Bisson R, Zeviani M.
A single cell complementation class is common to several cases of cytochrome
c oxidase-defective Leigh’s syndrome. Hum Mol Genet 1997;6:221–8.
20 Procaccio V, Mousson B, Beugnot R, Duborjal H, Feillet F, Putet G, Pignot-
Paintrand I, Lombes A, De Coo R, Smeets H, Lunardi J, Issartel JP. Nuclear
DNA origin of mitochondrial complex I deficiency in fatal infantile lactic
acidosis evidenced by transnuclear complementation of cultured fibroblasts.
J Clin Invest 1999;104:83–92.
21 Fearnley IM, Walker JE. Conservation of sequences of subunits of
mitochondrial complex-I and their relationships with other proteins. Biochim
Biophys Acta 1992;1140:105–34.
22 Fisher N, Rich PR. A motif for quinone binding sites in respiratory and
photosynthetic systems. J Mol Biol 2000;296:1153–62.
23 Zickermann V, Barquera B, Wikstrom M, Finel M. Analysis of the pathogenic
human mitochondrial mutation ND1/3460, and mutations of strictly
conserved residues in its vicinity, using the bacterium Paracoccus denitrificans.
Biochemistry 1998;37:11792–6.
24 Kurki S, Zickermann V, Kervinen M, Hassinen I, Finel M. Mutagenesis of three
conserved Glu residues in a bacterial homologue of the ND1 subunit of
complex I affects ubiquinone reduction kinetics but not inhibition by
dicyclohexylcarbodiimide. Biochemistry 2000;39:13496–502.
25 Darrouzet E, Issartel JP, Lunardi J, Dupuis A. The 49-kDa subunit of
NADH-ubiquinone oxidoreductase (complex I) is involved in the binding of
piericidin and rotenone, two quinone-related inhibitors. FEBS Lett
1998;431:34–8.
26 Roth R, Hagerhall C. Transmembrane orientation and topology of the
NADH:quinone oxidoreductase putative quinone binding subunit NuoH.
Biochim Biophys Acta 2001;1504:352–62.
27 Combet C, Blanchet C, Geourjon C, Deleage G. NPS@: network protein
sequence analysis. Trends Biochem Sci 2000;25:147–50.
28 Yao J, Shoubridge EA. Expression and functional analysis of SURF1 in Leigh
syndrome patients with cytochrome c oxidase deficiency. Hum Mol Genet
1999;8:2541–9.
29 Kirby DM, Kahler SG, Freckmann ML, Reddihough D, Thorburn DR. Leigh
disease caused by the mitochondrial DNA G14459A mutation in unrelated
families. Ann Neurol 2000;48:102–4.
Mitochondrial ND1 mutations in MELAS 789
www.jmedgenet.com
 group.bmj.com on January 18, 2010 - Published by jmg.bmj.comDownloaded from 
